卡瑞利珠单抗联合化疗用于我国宫颈癌患者的药物经济学评价

打开文本图片集

中图分类号R956 文献标志码A 文章编号 1001-0408（2025）14-1765-05

DOI 10.6039/j.issn.1001-0408.2025.14.13

ABSTRACTOBJECTIVEToperformapharmacoeconomicevaluationofcamrelizumabcombinedwithchemotherapyinthe treatmentof cervical cancer in China.METHODSFrom the perspectiveof China'shealthcare system，a Markov model was constructedbasedonliteraturedataregarding the treatmentofcervical cancer with camrelizumabcombined with chemotherapy， where theincidenceofadversereactions wasobtainedthroughameta-analysis.The modelwasrunovera1O-year time horizon with a3-weekcyclelength.Costsincludeddirectcosts（e.g.drugcost，adverseeventreatmentcost）.Utilityvalues werederivedfrom existing studies，and transition probabilities were calculated using literature data，with a discount rate of 5% ； the willingness-to-pay （WTP）thresholdwassetat3times China’s2024percapita grossdomestic product（GDP），i.e.287247yuan/quality-adjusted life year（QALY）.Cost-efectivenesswascomparedbetweencamrelizumabcombinedwithchemotherapyand monotherapy.One-way sensitivityanalysisandMonteCarlo simulation wereusedtoevaluate theimpactof parameter variationsonresults.RESULTS Comparedwithcamrelizumabmonotherapy，the incrementalcost-effectivenessratio（ICER）ofcamrelizumabcombinedwith chemotherapywas181507.58yuan/QALY，belowthepredefiedWTPthreshold.One-waysensitivityanalysisshowedthatthe outcomeswerelargelyafectedbytheprogresion-freesurvival-to-deathtransitionprobabilitiesinbothgroups.Probabilistic sensitivity analysis indicated a 91.8% probability of camrelizumab combined with chemotherapy being cost-effective at a WTP thresholdof3timesChina’s2024percapitaGDP.CONCLUSIONSFrom China’shealthcaresystem perspective，camrelizumab combinedwithchemotherapyiscost-effectiveforcervicalcancerinChina，comparedwithmonotherapy，whenusing3times China's 2024 per capita GDP as the WTP threshold.

KEYWORDS camrelizumab；cervical cancer；pharmacoeconomic evaluation

宫颈癌的发病率在全球女性常见肿瘤中居第4位。（剩余9133字）